A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Status:
Completed
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
This was a long-term follow-up study to evaluate the durability of sustained virologic
response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical
outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in
prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus
(HCV) infection.